WallStreetZenWallStreetZen

NASDAQ: GLYC
Glycomimetics Inc Stock

$0.27+0.01 (+3.85%)
Updated Jun 13, 2024
GLYC Price
$0.27
Fair Value Price
$0.65
Market Cap
$17.47M
52 Week Low
$0.25
52 Week High
$3.53
P/E
-0.47x
P/B
0.6x
P/S
19,337.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.00k
Earnings
-$37.28M
Gross Margin
100%
Operating Margin
-372,767.37%
Profit Margin
-372,767.4%
Debt to Equity
0.18
Operating Cash Flow
-$34M
Beta
1.18
Next Earnings
Jul 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A

GLYC Overview

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GLYC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GLYC ($0.27) is undervalued by 58.11% relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GLYC ($0.27) is significantly undervalued by 58.11% relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
GLYC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GLYC due diligence checks available for Premium users.

Be the first to know about important GLYC news, forecast changes, insider trades & much more!

GLYC News

Valuation

GLYC fair value

Fair Value of GLYC stock based on Discounted Cash Flow (DCF)
Price
$0.27
Fair Value
$0.65
Undervalued by
58.27%
GLYC ($0.27) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GLYC ($0.27) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GLYC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GLYC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.47x
Industry
-7.95x
Market
30.48x

GLYC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.6x
Industry
6.3x
GLYC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GLYC's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.7M
Profit Margin
0%
GLYC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GLYC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$34.2M
Liabilities
$5.3M
Debt to equity
0.18
GLYC's short-term assets ($33.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLYC's short-term assets ($33.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLYC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GLYC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.5M
Investing
-$7.4k
Financing
$4.9k
GLYC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GLYC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GLYC$17.47M+3.04%-0.47x0.60x
LGVN$17.08M+48.62%-0.28x5.62x
VBIV$16.81M-2.82%-0.10x-3.07x
PPBT$16.78M+2.31%N/A0.54x
JAGX$18.27M+0.54%-0.09x1.52x

Glycomimetics Stock FAQ

What is Glycomimetics's quote symbol?

(NASDAQ: GLYC) Glycomimetics trades on the NASDAQ under the ticker symbol GLYC. Glycomimetics stock quotes can also be displayed as NASDAQ: GLYC.

If you're new to stock investing, here's how to buy Glycomimetics stock.

What is the 52 week high and low for Glycomimetics (NASDAQ: GLYC)?

(NASDAQ: GLYC) Glycomimetics's 52-week high was $3.53, and its 52-week low was $0.25. It is currently -92.32% from its 52-week high and 7.97% from its 52-week low.

How much is Glycomimetics stock worth today?

(NASDAQ: GLYC) Glycomimetics currently has 64,464,412 outstanding shares. With Glycomimetics stock trading at $0.27 per share, the total value of Glycomimetics stock (market capitalization) is $17.47M.

Glycomimetics stock was originally listed at a price of $9.01 in Jan 10, 2014. If you had invested in Glycomimetics stock at $9.01, your return over the last 10 years would have been -96.99%, for an annualized return of -29.56% (not including any dividends or dividend reinvestments).

How much is Glycomimetics's stock price per share?

(NASDAQ: GLYC) Glycomimetics stock price per share is $0.27 today (as of Jun 13, 2024).

What is Glycomimetics's Market Cap?

(NASDAQ: GLYC) Glycomimetics's market cap is $17.47M, as of Jun 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Glycomimetics's market cap is calculated by multiplying GLYC's current stock price of $0.27 by GLYC's total outstanding shares of 64,464,412.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.